BACKGROUND: Airway infections with Pseudomonas aeruginosa often represent a life-threatening event in immuno-compromised patients or patients with Cystic Fibrosis. The adhesion of this bacterium to surfaces such as the airway epithelium is mediated by two lectins, sugar binding proteins. In addition to their adhesive properties, these lectins have been shown to stop human ciliary beating thus compromising the mucociliary clearance as an important non-specific defence mechanism of the airways. Inhibition of these lectins by their specific sugars galactose and fucose, respectively, could therefore be of benefit in the elimination therapy of P. aeruginosa. CASE REPORT: An infant suffering from P. aeruginosa airway infection after chemotherapy for neuroblastoma, which could not successfully be treated by antibiotics, was subjected to a series of additional galactose/fucose inhalations, which eliminated the germ as evidenced by microbiological testing. This is the first report suggesting the effectiveness of a lectin-based therapeutic principle in P. aeruginosa airway infection. CONCLUSION: The competitive inhibition of P. aeruginosa lectins by the lectin specific sugars galactose and fucose may overcome particular mechanisms of bacterial resistance in patients with P. aeruginosa airway infection. This underlying biochemical mechanism and the outcome of our patient suggest a clinical benefit of this novel therapeutic approach for immunocompromised patients or patients with cystic fibrosis suffering from infection with P. aeruginosa.
BACKGROUND:Airway infections with Pseudomonas aeruginosa often represent a life-threatening event in immuno-compromised patients or patients with Cystic Fibrosis. The adhesion of this bacterium to surfaces such as the airway epithelium is mediated by two lectins, sugar binding proteins. In addition to their adhesive properties, these lectins have been shown to stop human ciliary beating thus compromising the mucociliary clearance as an important non-specific defence mechanism of the airways. Inhibition of these lectins by their specific sugarsgalactose and fucose, respectively, could therefore be of benefit in the elimination therapy of P. aeruginosa. CASE REPORT: An infant suffering from P. aeruginosa airway infection after chemotherapy for neuroblastoma, which could not successfully be treated by antibiotics, was subjected to a series of additional galactose/fucose inhalations, which eliminated the germ as evidenced by microbiological testing. This is the first report suggesting the effectiveness of a lectin-based therapeutic principle in P. aeruginosa airway infection. CONCLUSION: The competitive inhibition of P. aeruginosa lectins by the lectin specific sugarsgalactose and fucose may overcome particular mechanisms of bacterial resistance in patients with P. aeruginosa airway infection. This underlying biochemical mechanism and the outcome of our patient suggest a clinical benefit of this novel therapeutic approach for immunocompromised patients or patients with cystic fibrosis suffering from infection with P. aeruginosa.
Authors: H Gustke; R Kleene; G Loers; N Nehmann; M Jaehne; K-M Bartels; K-E Jaeger; M Schachner; U Schumacher Journal: Eur J Clin Microbiol Infect Dis Date: 2011-05-22 Impact factor: 3.267
Authors: Iwona Bucior; Jason Abbott; Yuanlin Song; Michael A Matthay; Joanne N Engel Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-06-21 Impact factor: 5.464
Authors: Horst Funken; Kai-Malte Bartels; Susanne Wilhelm; Melanie Brocker; Michael Bott; Manjeet Bains; Robert E W Hancock; Frank Rosenau; Karl-Erich Jaeger Journal: PLoS One Date: 2012-10-08 Impact factor: 3.240
Authors: Rameshwar U Kadam; Myriam Bergmann; Matthew Hurley; Divita Garg; Martina Cacciarini; Magdalena A Swiderska; Cristina Nativi; Michael Sattler; Alan R Smyth; Paul Williams; Miguel Cámara; Achim Stocker; Tamis Darbre; Jean-Louis Reymond Journal: Angew Chem Int Ed Engl Date: 2011-09-14 Impact factor: 15.336
Authors: Hans-Peter Hauber; Maria Schulz; Almuth Pforte; Dietrich Mack; Peter Zabel; Udo Schumacher Journal: Int J Med Sci Date: 2008-11-17 Impact factor: 3.738